JP2015512939A - ヒストンデアセチラーゼ(hdacs)阻害剤 - Google Patents
ヒストンデアセチラーゼ(hdacs)阻害剤 Download PDFInfo
- Publication number
- JP2015512939A JP2015512939A JP2015505789A JP2015505789A JP2015512939A JP 2015512939 A JP2015512939 A JP 2015512939A JP 2015505789 A JP2015505789 A JP 2015505789A JP 2015505789 A JP2015505789 A JP 2015505789A JP 2015512939 A JP2015512939 A JP 2015512939A
- Authority
- JP
- Japan
- Prior art keywords
- oxo
- dihydro
- ethyl
- hydroxyacrylamide
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003964 Histone deacetylase Human genes 0.000 title claims abstract description 21
- 108090000353 Histone deacetylase Proteins 0.000 title claims abstract description 21
- 239000003112 inhibitor Substances 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 230000005764 inhibitory process Effects 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 112
- -1 N-hydroxyaminocarbonyl Chemical group 0.000 claims description 109
- 229910052739 hydrogen Inorganic materials 0.000 claims description 66
- 239000001257 hydrogen Substances 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 35
- 239000000651 prodrug Substances 0.000 claims description 26
- 229940002612 prodrug Drugs 0.000 claims description 26
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 19
- 239000012453 solvate Substances 0.000 claims description 17
- 239000002207 metabolite Substances 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- 150000002431 hydrogen Chemical class 0.000 claims description 14
- 239000003981 vehicle Substances 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 10
- 125000001153 fluoro group Chemical group F* 0.000 claims description 9
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- VAAWIYIVFTYJRI-VQHVLOKHSA-N (e)-n-hydroxy-3-[4-oxo-3-(2-phenylethyl)quinazolin-7-yl]prop-2-enamide Chemical compound C=1C(/C=C/C(=O)NO)=CC=C(C2=O)C=1N=CN2CCC1=CC=CC=C1 VAAWIYIVFTYJRI-VQHVLOKHSA-N 0.000 claims description 7
- 230000003831 deregulation Effects 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 230000004770 neurodegeneration Effects 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- NAMOJMZBPJZNOD-CMDGGOBGSA-N (e)-3-[2-ethyl-7-fluoro-4-oxo-3-(2-phenylethyl)quinazolin-6-yl]-n-hydroxyprop-2-enamide Chemical compound CCC1=NC2=CC(F)=C(\C=C\C(=O)NO)C=C2C(=O)N1CCC1=CC=CC=C1 NAMOJMZBPJZNOD-CMDGGOBGSA-N 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- DROCPQHWNIUOQA-CSKARUKUSA-N (e)-3-(3-benzyl-2-methyl-4-oxoquinazolin-7-yl)-n-hydroxyprop-2-enamide Chemical compound CC1=NC2=CC(\C=C\C(=O)NO)=CC=C2C(=O)N1CC1=CC=CC=C1 DROCPQHWNIUOQA-CSKARUKUSA-N 0.000 claims description 4
- KOGSPXQDGNAZKQ-YRNVUSSQSA-N (e)-3-[2-cyclopropyl-4-oxo-3-(2-phenylethyl)quinazolin-7-yl]-n-hydroxyprop-2-enamide Chemical compound C=1C(/C=C/C(=O)NO)=CC=C(C(N2CCC=3C=CC=CC=3)=O)C=1N=C2C1CC1 KOGSPXQDGNAZKQ-YRNVUSSQSA-N 0.000 claims description 4
- OSGSDDYIACXJCX-ACCUITESSA-N (e)-3-[2-ethyl-4-oxo-3-(3-phenylpropyl)quinazolin-7-yl]-n-hydroxyprop-2-enamide Chemical compound CCC1=NC2=CC(\C=C\C(=O)NO)=CC=C2C(=O)N1CCCC1=CC=CC=C1 OSGSDDYIACXJCX-ACCUITESSA-N 0.000 claims description 4
- RGKDACUEVSPDNA-CMDGGOBGSA-N (e)-3-[2-ethyl-6-fluoro-4-oxo-3-(2-phenylethyl)quinazolin-7-yl]-n-hydroxyprop-2-enamide Chemical compound CCC1=NC2=CC(\C=C\C(=O)NO)=C(F)C=C2C(=O)N1CCC1=CC=CC=C1 RGKDACUEVSPDNA-CMDGGOBGSA-N 0.000 claims description 4
- MDTWRJDWPUJHKT-CSKARUKUSA-N (e)-n-hydroxy-3-(2-methyl-4-oxo-3-phenylquinazolin-7-yl)prop-2-enamide Chemical compound CC1=NC2=CC(\C=C\C(=O)NO)=CC=C2C(=O)N1C1=CC=CC=C1 MDTWRJDWPUJHKT-CSKARUKUSA-N 0.000 claims description 4
- STSNTVHQAOSMDW-ZHACJKMWSA-N (e)-n-hydroxy-3-(2-methyl-4-oxo-3-phenylquinazolin-8-yl)prop-2-enamide Chemical compound CC1=NC2=C(\C=C\C(=O)NO)C=CC=C2C(=O)N1C1=CC=CC=C1 STSNTVHQAOSMDW-ZHACJKMWSA-N 0.000 claims description 4
- NVEBAMFLYZFKKW-CSKARUKUSA-N (e)-n-hydroxy-3-[2-methyl-4-oxo-3-(2-phenylethyl)quinazolin-7-yl]prop-2-enamide Chemical compound CC1=NC2=CC(\C=C\C(=O)NO)=CC=C2C(=O)N1CCC1=CC=CC=C1 NVEBAMFLYZFKKW-CSKARUKUSA-N 0.000 claims description 4
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 claims description 4
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- VERZRJYONMSRFY-UHFFFAOYSA-N 4-[2-ethyl-4-oxo-3-(2-phenylethyl)quinazolin-8-yl]-n-hydroxybenzamide Chemical compound CCC1=NC2=C(C=3C=CC(=CC=3)C(=O)NO)C=CC=C2C(=O)N1CCC1=CC=CC=C1 VERZRJYONMSRFY-UHFFFAOYSA-N 0.000 claims description 4
- LQAXATZNWUNYBS-UHFFFAOYSA-N 4-[[2-ethyl-4-oxo-3-(2-phenylethyl)quinazolin-7-yl]methyl]-n-hydroxybenzamide Chemical compound C=1C=C2C(=O)N(CCC=3C=CC=CC=3)C(CC)=NC2=CC=1CC1=CC=C(C(=O)NO)C=C1 LQAXATZNWUNYBS-UHFFFAOYSA-N 0.000 claims description 4
- HPCPCLJRBNRLLW-UHFFFAOYSA-N 4-[[2-ethyl-4-oxo-3-(2-phenylethyl)quinazolin-8-yl]methyl]-n-hydroxybenzamide Chemical compound C1=CC=C2C(=O)N(CCC=3C=CC=CC=3)C(CC)=NC2=C1CC1=CC=C(C(=O)NO)C=C1 HPCPCLJRBNRLLW-UHFFFAOYSA-N 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010029098 Neoplasm skin Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- HKISHKJJYBCZQL-UXBLZVDNSA-N (e)-3-[2-ethyl-3-[2-(4-fluorophenyl)ethyl]-4-oxoquinazolin-7-yl]-n-hydroxyprop-2-enamide Chemical compound CCC1=NC2=CC(\C=C\C(=O)NO)=CC=C2C(=O)N1CCC1=CC=C(F)C=C1 HKISHKJJYBCZQL-UXBLZVDNSA-N 0.000 claims description 3
- DWWXXRKGLLUOGK-YRNVUSSQSA-N (e)-3-[2-ethyl-3-[2-(4-methoxyphenyl)ethyl]-4-oxoquinazolin-7-yl]-n-hydroxyprop-2-enamide Chemical compound CCC1=NC2=CC(\C=C\C(=O)NO)=CC=C2C(=O)N1CCC1=CC=C(OC)C=C1 DWWXXRKGLLUOGK-YRNVUSSQSA-N 0.000 claims description 3
- AULBTEVAVDTQLP-PKNBQFBNSA-N (e)-3-[2-ethyl-4-oxo-3-(2-phenylethyl)quinazolin-7-yl]-n-hydroxyprop-2-enamide Chemical compound CCC1=NC2=CC(\C=C\C(=O)NO)=CC=C2C(=O)N1CCC1=CC=CC=C1 AULBTEVAVDTQLP-PKNBQFBNSA-N 0.000 claims description 3
- KUKBDBQCXIHWRC-ZHACJKMWSA-N (e)-n-hydroxy-3-(2-methyl-4-oxo-3-phenylquinazolin-5-yl)prop-2-enamide Chemical compound CC1=NC2=CC=CC(\C=C\C(=O)NO)=C2C(=O)N1C1=CC=CC=C1 KUKBDBQCXIHWRC-ZHACJKMWSA-N 0.000 claims description 3
- SDVRJMHVMXPKQZ-PKNBQFBNSA-N (e)-n-hydroxy-3-[4-oxo-3-(2-phenylethyl)-2-propan-2-ylquinazolin-7-yl]prop-2-enamide Chemical compound CC(C)C1=NC2=CC(\C=C\C(=O)NO)=CC=C2C(=O)N1CCC1=CC=CC=C1 SDVRJMHVMXPKQZ-PKNBQFBNSA-N 0.000 claims description 3
- VLBQAJZSHGGUBQ-UHFFFAOYSA-N 4-[[2-ethyl-4-oxo-3-(2-phenylethyl)quinazolin-6-yl]methyl]-n-hydroxybenzamide Chemical compound C1=C2C(=O)N(CCC=3C=CC=CC=3)C(CC)=NC2=CC=C1CC1=CC=C(C(=O)NO)C=C1 VLBQAJZSHGGUBQ-UHFFFAOYSA-N 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- JNOVVOHLHNGPOH-CSKARUKUSA-N (e)-n-hydroxy-3-(2-methyl-4-oxo-3-phenylquinazolin-6-yl)prop-2-enamide Chemical compound CC1=NC2=CC=C(\C=C\C(=O)NO)C=C2C(=O)N1C1=CC=CC=C1 JNOVVOHLHNGPOH-CSKARUKUSA-N 0.000 claims description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 2
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010023774 Large cell lung cancer Diseases 0.000 claims description 2
- 206010061328 Ovarian epithelial cancer Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 201000009546 lung large cell carcinoma Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000013371 ovarian adenocarcinoma Diseases 0.000 claims description 2
- 201000006588 ovary adenocarcinoma Diseases 0.000 claims description 2
- 201000001514 prostate carcinoma Diseases 0.000 claims description 2
- 201000001475 prostate lymphoma Diseases 0.000 claims description 2
- 208000023958 prostate neoplasm Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- WBEKWMCWJUVKEG-UHFFFAOYSA-N 2-[7-chloro-2-ethyl-4-oxo-3-(2-phenylethyl)quinazolin-6-yl]-N-hydroxyprop-2-enamide Chemical compound ClC1=C(C=C2C(N(C(=NC2=C1)CC)CCC1=CC=CC=C1)=O)C(C(=O)NO)=C WBEKWMCWJUVKEG-UHFFFAOYSA-N 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 22
- 229940121372 histone deacetylase inhibitor Drugs 0.000 abstract description 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 123
- 239000007787 solid Substances 0.000 description 39
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- 229910052799 carbon Inorganic materials 0.000 description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- 238000002360 preparation method Methods 0.000 description 29
- 229910052757 nitrogen Inorganic materials 0.000 description 27
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 238000001953 recrystallisation Methods 0.000 description 15
- 125000001072 heteroaryl group Chemical group 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 13
- 229910052740 iodine Inorganic materials 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 125000000753 cycloalkyl group Chemical group 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 125000003342 alkenyl group Chemical group 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 125000000623 heterocyclic group Chemical group 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 6
- 239000004215 Carbon black (E152) Substances 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 229930195733 hydrocarbon Natural products 0.000 description 6
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 5
- 102100022537 Histone deacetylase 6 Human genes 0.000 description 5
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 description 5
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 150000004677 hydrates Chemical class 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- LWUAMROXVQLJKA-UHFFFAOYSA-N 2-amino-3-chlorobenzoic acid Chemical compound NC1=C(Cl)C=CC=C1C(O)=O LWUAMROXVQLJKA-UHFFFAOYSA-N 0.000 description 4
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 125000004442 acylamino group Chemical group 0.000 description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 125000001589 carboacyl group Chemical group 0.000 description 4
- 125000004181 carboxyalkyl group Chemical group 0.000 description 4
- DGJMPUGMZIKDRO-UHFFFAOYSA-N cyanoacetamide Chemical compound NC(=O)CC#N DGJMPUGMZIKDRO-UHFFFAOYSA-N 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 210000002241 neurite Anatomy 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000014511 neuron projection development Effects 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- HVLLSGMXQDNUAL-UHFFFAOYSA-N triphenyl phosphite Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)OC1=CC=CC=C1 HVLLSGMXQDNUAL-UHFFFAOYSA-N 0.000 description 4
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 3
- DRLAOVNZDDOIAG-CMDGGOBGSA-N (e)-3-[7-chloro-2-ethyl-4-oxo-3-(2-phenylethyl)quinazolin-6-yl]-n-hydroxyprop-2-enamide Chemical compound CCC1=NC2=CC(Cl)=C(\C=C\C(=O)NO)C=C2C(=O)N1CCC1=CC=CC=C1 DRLAOVNZDDOIAG-CMDGGOBGSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229940125907 SJ995973 Drugs 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 3
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 238000010825 rotarod performance test Methods 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 210000000225 synapse Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 2
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 2
- VAVHMEQFYYBAPR-ITWZMISCSA-N (e,3r,5s)-7-[4-(4-fluorophenyl)-1-phenyl-2-propan-2-ylpyrrol-3-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(C=2C=CC(F)=CC=2)=CN1C1=CC=CC=C1 VAVHMEQFYYBAPR-ITWZMISCSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- YJJLFAHVYWIRAC-UHFFFAOYSA-N 8-chloro-2-ethyl-3-(2-phenylethyl)quinazolin-4-one Chemical compound CCC1=NC2=C(Cl)C=CC=C2C(=O)N1CCC1=CC=CC=C1 YJJLFAHVYWIRAC-UHFFFAOYSA-N 0.000 description 2
- VCUKKMIXURRDKL-UHFFFAOYSA-N 9-(dimethylamino)-3-(4-ethylphenyl)pyrido[1,2]thieno[3,4-d]pyrimidin-4-one Chemical compound C1=CC(CC)=CC=C1N1C(=O)C(SC=2C3=C(N(C)C)C=CN=2)=C3N=C1 VCUKKMIXURRDKL-UHFFFAOYSA-N 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DGJMHKMYSDYOFP-MRXNPFEDSA-N C=CC(N(CCC1)C[C@@H]1N1N=C(C2=CN(CC(C3=CC=CC=C3)(F)F)N=N2)C2=C(N)N=CN=C12)=O Chemical compound C=CC(N(CCC1)C[C@@H]1N1N=C(C2=CN(CC(C3=CC=CC=C3)(F)F)N=N2)C2=C(N)N=CN=C12)=O DGJMHKMYSDYOFP-MRXNPFEDSA-N 0.000 description 2
- 101150065749 Churc1 gene Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 2
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102100038239 Protein Churchill Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- BEXZJJQVPWJPOA-VOTSOKGWSA-N [(e)-hept-2-enyl] 6-methyl-4-(4-nitrophenyl)-2-oxo-3,4-dihydro-1h-pyrimidine-5-carboxylate Chemical compound CCCC\C=C\COC(=O)C1=C(C)NC(=O)NC1C1=CC=C([N+]([O-])=O)C=C1 BEXZJJQVPWJPOA-VOTSOKGWSA-N 0.000 description 2
- HGDWHTASNMRJMP-UHFFFAOYSA-N [1-(hydroxyamino)-1-oxo-5-(3-phenoxyphenyl)pentan-2-yl]phosphonic acid Chemical compound ONC(=O)C(P(O)(O)=O)CCCC1=CC=CC(OC=2C=CC=CC=2)=C1 HGDWHTASNMRJMP-UHFFFAOYSA-N 0.000 description 2
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 230000006933 amyloid-beta aggregation Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229940117803 phenethylamine Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- PQCXFUXRTRESBD-UHFFFAOYSA-N (4-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=CC=C(B(O)O)C=C1 PQCXFUXRTRESBD-UHFFFAOYSA-N 0.000 description 1
- JNPGUXGVLNJQSQ-BGGMYYEUSA-M (e,3r,5s)-7-[4-(4-fluorophenyl)-1,2-di(propan-2-yl)pyrrol-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)N1C(C(C)C)=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C1 JNPGUXGVLNJQSQ-BGGMYYEUSA-M 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- IFXKXCLVKQVVDI-UHFFFAOYSA-N 2-amino-5-chlorobenzoic acid Chemical compound NC1=CC=C(Cl)C=C1C(O)=O IFXKXCLVKQVVDI-UHFFFAOYSA-N 0.000 description 1
- YZCZSYPALZQUEI-UHFFFAOYSA-N 2-ethyl-7-fluoro-6-iodo-3-(2-phenylethyl)quinazolin-4-one Chemical compound CCC1=NC2=CC(F)=C(I)C=C2C(=O)N1CCC1=CC=CC=C1 YZCZSYPALZQUEI-UHFFFAOYSA-N 0.000 description 1
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004922 2-methyl-3-pentyl group Chemical group CC(C)C(CC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 1
- NDBWXABZJZQZPX-UHFFFAOYSA-N 4-chloro-5-fluoro-2-(propanoylamino)benzoic acid Chemical compound CCC(=O)NC1=CC(Cl)=C(F)C=C1C(O)=O NDBWXABZJZQZPX-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- HIHOEGPXVVKJPP-JTQLQIEISA-N 5-fluoro-2-[[(1s)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1N=CC(F)=CC=1)C(C(=CC=1F)C#N)=NC=1NC=1C=C(C)NN=1 HIHOEGPXVVKJPP-JTQLQIEISA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- XFXUNVNKYWEQEE-UHFFFAOYSA-N 7-chloro-2-ethyl-6-fluoro-3-(2-phenylethyl)quinazolin-4-one Chemical compound CCC1=NC2=CC(Cl)=C(F)C=C2C(=O)N1CCC1=CC=CC=C1 XFXUNVNKYWEQEE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102100038715 Histone deacetylase 8 Human genes 0.000 description 1
- 101001032118 Homo sapiens Histone deacetylase 8 Proteins 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000872931 Myoporum sandwicense Species 0.000 description 1
- JNOVVOHLHNGPOH-UHFFFAOYSA-N N-hydroxy-3-(2-methyl-4-oxo-3-phenylquinazolin-6-yl)prop-2-enamide Chemical compound CC1=NC2=CC=C(C=CC(=O)NO)C=C2C(=O)N1C1=CC=CC=C1 JNOVVOHLHNGPOH-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 210000003737 chromaffin cell Anatomy 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940125890 compound Ia Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 description 1
- 210000003237 epithelioid cell Anatomy 0.000 description 1
- GJAIRCQJMDRARQ-ZRDIBKRKSA-N ethyl (e)-3-(2-methyl-4-oxo-3-phenylquinazolin-6-yl)prop-2-enoate Chemical compound O=C1C2=CC(/C=C/C(=O)OCC)=CC=C2N=C(C)N1C1=CC=CC=C1 GJAIRCQJMDRARQ-ZRDIBKRKSA-N 0.000 description 1
- TWQLMAJROCNXEA-UHFFFAOYSA-N ethyl 4-(bromomethyl)benzoate Chemical compound CCOC(=O)C1=CC=C(CBr)C=C1 TWQLMAJROCNXEA-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 230000004694 hippocampus damage Effects 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000007786 learning performance Effects 0.000 description 1
- JFOZKMSJYSPYLN-QHCPKHFHSA-N lifitegrast Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C=2C(=C3CCN(CC3=CC=2Cl)C(=O)C=2C=C3OC=CC3=CC=2)Cl)C(O)=O)=C1 JFOZKMSJYSPYLN-QHCPKHFHSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- FEXRDGZOCZIRRY-UHFFFAOYSA-N methyl 4-[2-ethyl-4-oxo-3-(2-phenylethyl)quinazolin-8-yl]benzoate Chemical compound CCC1=NC2=C(C=3C=CC(=CC=3)C(=O)OC)C=CC=C2C(=O)N1CCC1=CC=CC=C1 FEXRDGZOCZIRRY-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- PPSIXQBQDCJBKF-UHFFFAOYSA-N n-(2-bromo-5-chloro-4-fluorophenyl)propanamide Chemical compound CCC(=O)NC1=CC(Cl)=C(F)C=C1Br PPSIXQBQDCJBKF-UHFFFAOYSA-N 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003522 neurite outgrowth assay Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000004932 phenoxathinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 231100000338 sulforhodamine B assay Toxicity 0.000 description 1
- 238000003210 sulforhodamine B staining Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
本発明は、概して、ヒストンデアセチラーゼ阻害剤に関する。
WO2008040934, WO2008068170, WO/2008/087514, WO/2009/026446, WO/2009/045440, WO/2011/011186, U.S. Patent Nos. 8,188,138; 8,058,273, 及び7,803,800は、抗腫瘍活性及び抗神経変性(antineurondegenerative)活性を有するヒストンデアセチラーゼ(HDAC)阻害剤を開示している。
一つの態様では、本発明は、以下の構造を有する化合物
R1は、水素、(C1-C6)アルキル又は(C3-C6)シクロアルキルであり;
R2は、(C6-C18)アリール、(C6-C18)アリール(C1-C6)アルキル、(C3-C18)ヘテロアリール(C1-C6)アルキル、ハロ(C6-C18)アリール(C1-C6)アルキル又は(C1-C6)アルコキシ(C6-C18)アリール(C1-C6)アルキルであり;
R3は、水素又はN-ヒドロキシアミノ-オキソ(C2-C6)アルケニルであり;
R4は、水素、ハロゲン、N-ヒドロキシアミノ-オキソ(C2-C6)アルケニル又はN-ヒドロキシアミノカルボニル(C6-C18)アリール(C1-C6)アルキレンであり;
R5は、水素、ハロゲン、N-ヒドロキシアミノ-オキソ(C2-C6)アルケニル、N-ヒドロキシアミノカルボニル(C6-C18)アリール(C1-C6)アルキレン又はアミノ(C6-C18)アリール-オキソ(C2-C6)アルケニルであり;
R6は、水素、N-ヒドロキシアミノ-オキソ(C2-C6)アルケニル、N-ヒドロキシアミノ(C6-C18)アリール(C1-C6)アルキレン又はN-ヒドロキシアミノカルボニル(C6-C18)アリール(C1-C6)アルキレンである。
R1は、水素、メチル、エチル、シクロプロピル又はイソプロピルであり;
R2は、フェニル、ベンジル、2-フェニルエチル、3-フェニルプロピル、2-(1H-インドール-3-イル)エチル、2-(4-フルオロフェニル)エチル又は2-(4-メトキシフェニル)エチルであり;
R3は、水素又は(2E)-3-N-ヒドロキシアミノ-3-オキソ-プロペニルであり;
R4は、水素、フルオロ、(2E)-3-N-ヒドロキシアミノ-3-オキソ-プロペニル又は4-(N-ヒドロキシアミノカルボニル)ベンジルであり;
R5は、水素、クロル、フルオロ、(2E)-3-N-ヒドロキシアミノ-3-オキソ-プロペニル、4-(N-ヒドロキシアミノカルボニル)ベンジル又は(2E)-3-N-(2-アミノフェニル)-3-オキソ-プロペニルであり;
R6は、水素、(2E)-3-N-ヒドロキシアミノ-3-オキソ-プロペニル、4-(N-ヒドロキシアミノカルボニル)フェニル又は4-(N-ヒドロキシアミノカルボニル)ベンジル又は、その塩である。
R1は、水素、メチル、エチル、シクロプロピル又はイソプロピルであり;
R2は、フェニル、ベンジル、2-フェニルエチル、3-フェニルプロピル、2-(1H-インドール-3-イル)エチル、2-(4-フルオロフェニル)エチル又は2-(4-メトキシフェニル)エチルであり;
R3は、水素又は(2E)-3-N-ヒドロキシアミノ-3-オキソ-プロペニルであり;
R4は、水素、(2E)-3-N-ヒドロキシアミノ-3-オキソ-プロペニル又は4-(N-ヒドロキシアミノカルボニル)ベンジルであり;
R5は、水素、(2E)-3-N-ヒドロキシアミノ-3-オキソ-プロペニル、4-(N-ヒドロキシアミノカルボニル)ベンジル又は(2E)-3-N-(2-アミノフェニル)-3-オキソ-プロペニルであり;
R6は、水素、(2E)-3-N-ヒドロキシアミノ-3-オキソ-プロペニル、4-(N-ヒドロキシアミノカルボニル)フェニル又は4-(N-ヒドロキシアミノカルボニル)ベンジル又はその塩である。
R1は、エチルであり;
R2は、2-フェニルエチルであり;
R3は、水素であり;
R4は、フルオロであり;
R5は、(2E)-3-N-ヒドロキシアミノ-3-オキソ-プロペニルであり;
R6は、水素又はその塩である。
R1は、エチルであり;
R2は、2-フェニルエチルであり;
R3は、水素であり;
R4は、(2E)-3-N-ヒドロキシアミノ-3-オキソ-プロペニルであり;
R5は、クロル又はフルオロであり;
R6は、水素又はその塩である。
定義
別途規定されない限り、本願明細書において用いられる全ての技術的及び科学的な用語は、本発明が関係する当業者によって一般に理解されるものと同じ意味である。不一致の場合、定義を含む本文献が支配的となるだろう。
本明細書に記載の化合物は、適用可能な任意の有機合成技術によって作成することができる。かかる技術の多くは、従来技術として知られている。"Compendium of Organic Synthetic Methods" (John Wiley & Sons, New York) Vol. 1, Ian T. Harrison and Shuyen Harrison (1971); Vol. 2, Ian T. Harrison and Shuyen Harrison (1974); Vol. 3, Louis S. Hegedus and Leroy Wade (1977); Vol. 4, Leroy G. Wade Jr., (1980)を参照。本明細書に記載の化合物を作成する例示的な方法は、下記実施例において本明細書に記載されているものとする。
一般式Xの化合物は、以下のスキームの手順によって作成される:
N-ヒドロキシ-3-(2-メチル-4-オキソ-3-フェニル-3,4-ジヒドロ-キナゾリン-6-イル)-アクリルアミド(化合物1b)の調製
ステップ1:
6-クロロ-2-メチル-3-フェニルキナゾリン-4(3H)-オンの調製
(2E)-エチル3-(3,4-ジヒドロ-2-メチル-4-オキソ-3-フェニルキナゾリン-6-イル)アクリレートの調製
(2E)-3-(3,4-ジヒドロ-2-メチル-4-オキソ-3-フェニルキナゾリン-6-イル)-N-ヒドロキシアクリルアミド(化合物1b)の調製
(2E)-3-(2-エチル-6-フルオロ-3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-7-イル)-N-ヒドロキシアクリルアミド(化合物2a)の調製
ステップ1:
N-(3-クロロ-4-フルオロフェニル)プロピオンアミドの調製
N-(2-ブロモ-5-クロロ-4-フルオロフェニル)プロピオンアミドの調製
4-クロロ-5-フルオロ-2-(プロピオンアミド)安息香酸の調製
7-クロロ-2-エチル-6-フルオロ-3-フェネチルキナゾリン-4(3H)-オンの調製
(2E)-エチル3-(2-エチル-6-フルオロ-3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-7-イル)アクリレートの調製
(2E)-3-(2-エチル-6-フルオロ-3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-7-イル)-N-ヒドロキシアクリルアミド(化合物2a)の調製
(2E)-3-(2-エチル-7-フルオロ-3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-6-イル)-N-ヒドロキシアクリルアミド(3a)の調製
ステップ1:
2-アミノ-4-フルオロ-5-ヨード安息香酸の調製
2-エチル-7-フルオロ-6-ヨード-3-フェネチルキナゾリン-4(3H)-オンの調製
(2E)-エチル3-(2-エチル-7-フルオロ-3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-6-イル)アクリレートの調製
(2E)-3-(2-エチル-7-フルオロ-3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-6-イル)-N-ヒドロキシアクリルアミド(3a)の調製
4-((2-エチル-3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-8-イル)メチル)-N-ヒドロキシベンズアミド(化合物4c)の調製
ステップ1:
8-クロロ-2-エチル-3-フェネチルキナゾリン-4(3H)-オンの調製
エチル4-((2-エチル-3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-8-イル)メチル)ベンゾエートの調製
4-((2-エチル-3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-8-イル)メチル)-N-ヒドロキシベンズアミド(化合物4c)の調製
4-(2-エチル-3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-8-イル)-N-ヒドロキシベンズアミド(化合物5a)の調製
ステップ1:
8-クロロ-2-エチル-3-フェネチルキナゾリン-4(3H)-オンの調製
メチル4-(2-エチル-3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-8-イル)ベンゾエートの調製
4-(2-エチル-3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-8-イル)-N-ヒドロキシベンズアミド(化合物5a)の調製
(2E)-N-(2-アミノフェニル)-3-(3,4-ジヒドロ-2-メチル-4-オキソ-3-フェネチルキナゾリン-7-イル)アクリルアミド(化合物6a)の調製
ステップ1:
7-クロロ-2-メチル-3-フェネチルキナゾリン-4(3H)-オンの調製
(2E)-エチル3-(3,4-ジヒドロ-2-メチル-4-オキソ-3-フェネチルキナゾリン-7-イル)アクリレートの調製
(2E)-N-(2-アミノフェニル)-3-(3,4-ジヒドロ-2-メチル-4-オキソ-3-フェネチルキナゾリン-7-イル)アクリルアミド(化合物6a)の調製
(2E)-3-(3,4-ジヒドロ-2-メチル-4-オキソ-3-フェニルキナゾリン-5-イル)-N-ヒドロキシアクリルアミド(1a)
(2E)-3-(7-クロル-2-エチル-3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-6-イル)-N-ヒドロキシアクリルアミド(3b)
4-((2-エチル-3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-6-イル)メチル)-N-ヒドロキシベンズアミド(4a)
これらの化合物は、ヒトヒストンデアセチラーゼ(HDAC) 1,2,3,6,8,10及び11に対する阻害作用を有していた。IC50値は、以下の等級区分IからIVを用いて決定した: Iは、≧10μMのIC50を表し、IIは、>1μMであるが<10μMのIC50を表し、IIIは、>0.1μMであるが<1μMのIC50表し、IVは、≦0.1μMのIC50を表す。HDAC酵素アッセイ方法は、従来技術として知られている。これらの化合物は、それぞれ、以下の通りのIC50にて、HDAC1、HDAC6及びHDAC8を阻害することが明らかになった:それぞれ、化合物Ia:I、IV及びII、化合物Ib、1m、1n、3a:II、IV及びIII、化合物Id、4c:I、III及びIII、化合物Ic、Ie、If、Ii、Ij、2a:II、IV及びII、化合物1g:III、IV及びII、化合物1h:III、IV及びIII、化合物2a:II、IV及びII、化合物3b:I、III及びII、化合物4a:II、IV及びIV、化合物6a:II、I及びI。
これらの化合物を、以下の細胞に対する細胞毒性についてアッセイした:A549細胞(ヒト肺胞基底上皮腺癌細胞)、HCT-116細胞(ヒト結腸癌細胞)、PANC-1細胞(ヒト膵癌、上皮様細胞株)及びHepG2細胞(ヒト肝癌細胞株)、神経細胞PC12(ラットクロム親和性細胞腫細胞株)及びSH-SY5Y(ヒト神経芽腫細胞株)。MTT(3-[4,5-ジメチルチアゾール-2-イル]2,5-ジフェニルテトラゾリウムブロミド)還元は、トリパンブルー除外アッセイを用いて共同して行った。
神経突起伸長に対する化合物の効果は、PC 12及びSH-SY5Y細胞にてアッセイした。これらの化合物は、以下の通りのEC50(μM)にて神経突起伸長を促進又は増進させることが明らかになった:それぞれ、化合物1c:15.86±2.03及び12.68±1.54 8.21±0.37及び8.20±0.92、化合物1f:6.49±0.78及び6.77±0.96、化合物1h:14.51±1.47及び4.93±1.34、化合物1i:7.21±0.32及び0.88±0.45、化合物1j:6.95±0.82、9.97±1.17、化合物1k:0.76±0.69及び>30、化合物1l:5.28±0.51及び6.74±0.78、化合物1m:20.62±3.12及び20.62±2.51、化合物1n:13.92±0.94及び22.17±2.01、化合物3b:10.71±1.26及び7.63±0.74、化合物4a:2.89±0.45及び4.06±0.58、化合物6a:6.59±1.06及び8.81±1.04μM。スチューデントt検定(p < 0.005)。したがって、これらの化合物は、神経変性疾患の治療に使用可能である。
β-アミロイド凝集の阻害に関する化合物の効果をアッセイした。β-アミロイド凝集体のレベルは、チオフラビンS、BCA又はCRアッセイによって決定した(表1)。チオフラビンS及びコンゴーレッドは、凝集β-アミロイドのインビトロ染色のためのものである。ビシンコニン酸(BCA)アッセイは、総タンパク質レベル又は濃度を決定する。
蛍光指示薬FM1-43の神経突起シナプス取り込みに関する化合物の効果をアッセイした。染料の取り込みが神経突起のシナプスの機能を明らかにした。PC 12及びSH-SY5Y細胞を使用した。実験群の細胞は、テスト化合物及びFM1-43を用いて処理した;ポジティブコントロールの細胞は、NGF及びFM1-43を用いて処理した;ネガティブコントロールの細胞は、ビヒクル及びFM1-43を用いて処理した。ポジティブコントロールにおける蛍光を100%とした。
アルツハイマー病モデルの動物における学習能力の向上に関する化合物の効果を試験するために、β-凝集体誘導海馬損傷を用いて学習障害マウスを作成した。海馬障害マウスは、化合物1c及び1fを用いて処置した(30日間、毎日、i.p. 10mg/kg)。図1は、ロータロッド試験の結果を示す。化合物1c及び1fは、海馬障害マウスにおけるコントロール(ビヒクル)と比較して、学習成績を向上させた。
Claims (15)
- 以下の構造を有する化合物
R1は、水素、(C1-C6)アルキル又は(C3-C6)シクロアルキルであり;
R2は、(C6-C18)アリール、(C6-C18)アリール(C1-C6)アルキル、(C3-C18)ヘテロアリール(C1-C6)アルキル、ハロ(C6-C18)アリール(C1-C6)アルキル又は(C1-C6)アルコキシ(C6-C18)アリール(C1-C6)アルキルであり;
R3は、水素又はN-ヒドロキシアミノ-オキソ(C2-C6)アルケニルであり;
R4は、水素、ハロゲン、N-ヒドロキシアミノ-オキソ(C2-C6)アルケニル又はN-ヒドロキシアミノカルボニル(C6-C18)アリール(C1-C6)アルキレンであり;
R5は、水素、ハロゲン、N-ヒドロキシアミノ-オキソ(C2-C6)アルケニル、N-ヒドロキシアミノカルボニル(C6-C18)アリール(C1-C6)アルキレン又はアミノ(C6-C18)アリール-オキソ(C2-C6)アルケニルであり;
R6は、水素、N-ヒドロキシアミノ-オキソ(C2-C6)アルケニル、N-ヒドロキシアミノ(C6-C18)アリール(C1-C6)アルキレン又はN-ヒドロキシアミノカルボニル(C6-C18)アリール(C1-C6)アルキレンである、化学式Xの構造を有する化合物又はその医薬的に許容可能な塩、溶媒和物又は水和物、プロドラッグ又は代謝産物。 - R1は、水素、メチル、エチル、シクロプロピル又はイソプロピルであり;
R2は、フェニル、ベンジル、2-フェニルエチル、3-フェニルプロピル、2-(1H-インドール-3-イル)エチル、2-(4-フルオロフェニル)エチル又は2-(4-メトキシフェニル)エチルであり;
R3は、水素又は(2E)-3-N-ヒドロキシアミノ-3-オキソ-プロペニルであり;
R4は、水素、フルオロ、(2E)-3-N-ヒドロキシアミノ-3-オキソ-プロペニル又は4-(N-ヒドロキシアミノカルボニル)ベンジルであり;
R5は、水素、クロル、フルオロ、(2E)-3-N-ヒドロキシアミノ-3-オキソ-プロペニル、4-(N-ヒドロキシアミノカルボニル)ベンジル又は(2E)-3-N-(2-アミノフェニル)-3-オキソ-プロペニルであり;
R6は、水素、(2E)-3-N-ヒドロキシアミノ-3-オキソ-プロペニル、4-(N-ヒドロキシアミノカルボニル)フェニル又は4-(N-ヒドロキシアミノカルボニル)ベンジル又はその塩である、請求項1に記載の化合物。 - R1は、水素、メチル、エチル、シクロプロピル又はイソプロピルであり;
R2は、フェニル、ベンジル、2-フェニルエチル、3-フェニルプロピル、2-(1H-インドール-3-イル)エチル、2-(4-フルオロフェニル)エチル又は2-(4-メトキシフェニル)エチルであり;
R3は、水素又は(2E)-3-N-ヒドロキシアミノ-3-オキソ-プロペニルであり;
R4は、水素、(2E)-3-N-ヒドロキシアミノ-3-オキソ-プロペニル又は4-(N-ヒドロキシアミノカルボニル)ベンジルであり;
R5は、水素、(2E)-3-N-ヒドロキシアミノ-3-オキソ-プロペニル、4-(N-ヒドロキシアミノカルボニル)ベンジル又は(2E)-3-N-(2-アミノフェニル)-3-オキソ-プロペニルであり;
R6は、水素、(2E)-3-N-ヒドロキシアミノ-3-オキソ-プロペニル、4-(N-ヒドロキシアミノカルボニル)フェニル又は4-(N-ヒドロキシアミノカルボニル)ベンジル又はその塩である、請求項2に記載の化合物。 - R1は、エチルであり;
R2は、2-フェニルエチルであり;
R3は、水素であり;
R4は、フルオロであり;
R5は、(2E)-3-N-ヒドロキシアミノ-3-オキソ-プロペニルであり;
R6は、水素又はその塩である、請求項2に記載の化合物。 - R1は、エチルであり;
R2は、2-フェニルエチルであり;
R3は、水素であり;
R4は、(2E)-3-N-ヒドロキシアミノ-3-オキソ-プロペニルであり;
R5は、クロル又はフルオロであり;
R6は、水素又はその塩である、請求項2に記載の化合物。 - 前記化合物は、
(2E)-3-(3,4-ジヒドロ-2-メチル-4-オキソ-3-フェニルキナゾリン-5-イル)-N-ヒドロキシアクリルアミド、
(2E)-3-(3,4-ジヒドロ-2-メチル-4-オキソ-3-フェニルキナゾリン-6-イル)-N-ヒドロキシアクリルアミド、
(2E)-3-(3,4-ジヒドロ-2-メチル-4-オキソ-3-フェニルキナゾリン-7-イル)-N-ヒドロキシアクリルアミド、
(2E)-3-(3,4-ジヒドロ-2-メチル-4-オキソ-3-フェニルキナゾリン-8-イル)-N-ヒドロキシアクリルアミド、
(2E)-3-(3-ベンジル-3,4-ジヒドロ-2-メチル-4-オキソキナゾリン-7-イル)-N-ヒドロキシアクリルアミド、
(2E)-3-(3,4-ジヒドロ-2-メチル-4-オキソ-3-フェネチルキナゾリン-7-イル)-N-ヒドロキシアクリルアミド、
(2E)-3-(3-(2-(1H-インドール-3-イル)エチル)-3,4-ジヒドロ-2-メチル-4-オキソキナゾリン-7-イル)-N-ヒドロキシアクリルアミド、
(2E)-3-(3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-7-イル)-N-ヒドロキシアクリルアミド、
(2E)-3-(2-エチル-3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-7-イル)-N-ヒドロキシアクリルアミド、
(2E)-3-(2-エチル-3,4-ジヒドロ-4-オキソ-3-(3-フェニルプロピル)キナゾリン-7-イル)-N-ヒドロキシアクリルアミド、
(2E)-3-(2-シクロプロピル-3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-7-イル)-N-ヒドロキシアクリルアミド、
(2E)-3-(3,4-ジヒドロ-2-イソプロピル-4-オキソ-3-フェネチルキナゾリン-7-イル)-N-ヒドロキシアクリルアミド、
(2E)-3-(3-(4-メトキシフェネチル)-2-エチル-3,4-ジヒドロ-4-オキソキナゾリン-7-イル)-N-ヒドロキシアクリルアミド、
(2E)-3-(3-(4-フルオロフェネチル)-2-エチル-3,4-ジヒドロ-4-オキソキナゾリン-7-イル)-N-ヒドロキシアクリルアミド、
4-((2-エチル-3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-6-イル)メチル)-N-ヒドロキシベンズアミド、
4-((2-エチル-3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-7-イル)メチル)-N-ヒドロキシベンズアミド、
4-((2-エチル-3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-8-イル)メチル)-N-ヒドロキシベンズアミド、
4-(2-エチル-3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-8-イル)-N-ヒドロキシベンズアミド、及び
(2E)-N-(2-アミノフェニル)-3-(3,4-ジヒドロ-2-メチル-4-オキソ-3-フェネチルキナゾリン-7-イル)アクリルアミドからなる群より選択される、請求項2に記載の化合物。 - 前記化合物は、(2E)-3-(2-エチル-6-フルオロ-3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-7-イル)-N-ヒドロキシアクリルアミド又はその塩である、請求項2に記載の化合物。
- 前記化合物は、(2E)-3-(2-エチル-7-フルオロ-3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-6-イル)-N-ヒドロキシアクリルアミド、(2E)-3-(7-クロル-2-エチル-3,4-ジヒドロ-4-オキソ-3-フェネチルキナゾリン-6-イル)-N-ヒドロキシアクリルアミド又はその塩である、請求項2に記載の化合物。
- 治療上有効な量の請求項1〜8のいずれかに記載の化合物又はその医薬的に許容可能な塩、溶媒和物又は水和物、プロドラッグ又は代謝産物、及び医薬的に許容可能なキャリア又はビヒクルを含む組成物。
- 治療上有効な量の請求項1〜8のいずれかに記載の化合物又はその医薬的に許容可能な塩、溶媒和物又は水和物、プロドラッグ又は代謝産物、及び医薬的に許容可能なキャリア又はビヒクルを含む、ヒストンデアセチラーゼ活性の調節解除に伴う腫瘍疾患を治療するために使用する組成物。
- 前記ヒストンデアセチラーゼ活性の調節解除に伴う前記疾患は、膵癌、肝癌、結腸腫瘍、乳房腫瘍、前立腺腫瘍、リンパ腫、及び皮膚腫瘍からなる群より選択される少なくとも1つの腫瘍である、請求項10に記載のヒストンデアセチラーゼ活性の調節解除を伴う腫瘍疾患を治療するために使用する組成物。
- 前記皮膚腫瘍疾患は、メラノーマ及び基底カルチノーマからなる群より選択される少なくとも1つである、請求項11に記載のヒストンデアセチラーゼ活性の調節解除に伴う腫瘍疾患を治療するために使用する組成物。
- 治療上有効な量の請求項1〜8のいずれかに記載の化合物又はその医薬的に許容可能な塩、溶媒和物又は水和物、プロドラッグ又は代謝産物、及び医薬的に許容可能なキャリア又はビヒクルを含む、乳癌、大腸癌、大細胞肺癌、肺の腺癌、小細胞肺癌、胃癌、肝癌、卵巣腺癌、膵臓カルチノーマ、前立腺カルチノーマ、前骨髄球性白血病、慢性骨髄性白血病又は急性リンパ性白血病に苦む対象を治療するための組成物。
- 治療上有効な量の請求項1〜8のいずれかに記載の化合物又はその医薬的に許容可能な塩、溶媒和物又は水和物、プロドラッグ又は代謝産物、及び医薬的に許容可能なキャリア又はビヒクルを含む、ハンチントン舞踏病(HD)、アルツハイマー病(AD)、パーキンソン病(PD)及び筋萎縮性側索硬化症(ALS)からなる群より選択される、神経変性疾患を治療するために使用する組成物。
- 治療上有効な量の請求項1〜8のいずれかに記載の化合物又はその医薬的に許容可能な塩、溶媒和物又は水和物、プロドラッグ又は代謝産物、及び医薬的に許容可能なキャリア又はビヒクルを含む、疾患又は状態を治療するために使用する組成物であって、HDACの阻害が利益をもたらすものである、組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261622127P | 2012-04-10 | 2012-04-10 | |
US61/622,127 | 2012-04-10 | ||
PCT/US2013/035004 WO2013154870A1 (en) | 2012-04-10 | 2013-04-02 | Histone deacetylases (hdacs) inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015512939A true JP2015512939A (ja) | 2015-04-30 |
JP2015512939A5 JP2015512939A5 (ja) | 2016-06-02 |
JP6258918B2 JP6258918B2 (ja) | 2018-01-10 |
Family
ID=49292802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015505789A Active JP6258918B2 (ja) | 2012-04-10 | 2013-04-02 | ヒストンデアセチラーゼ(hdacs)阻害剤 |
Country Status (13)
Country | Link |
---|---|
US (2) | US9387209B2 (ja) |
EP (1) | EP2836484B1 (ja) |
JP (1) | JP6258918B2 (ja) |
KR (1) | KR101781922B1 (ja) |
CN (1) | CN104364237B (ja) |
AU (1) | AU2013246278B2 (ja) |
BR (1) | BR112014025122B1 (ja) |
ES (1) | ES2630062T3 (ja) |
IL (1) | IL235053A (ja) |
IN (1) | IN2014MN02104A (ja) |
RU (1) | RU2629947C2 (ja) |
TW (1) | TWI481597B (ja) |
WO (1) | WO2013154870A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020519567A (ja) * | 2017-05-16 | 2020-07-02 | アンジー ファーマスーティカル シーオー.,エルティーディー.Annji Pharmaceutical Co., Ltd. | ヒストンデアセチラーゼ(hdacs)阻害剤 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103889656B (zh) | 2011-09-12 | 2017-03-15 | 应用材料公司 | 具有复合塑胶部分的载体头部 |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
JP6466924B2 (ja) | 2013-10-04 | 2019-02-06 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 複素環式化合物及びその使用 |
EP3114109A4 (en) * | 2014-03-07 | 2017-10-18 | The Johns Hopkins University | Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs) |
DK3119397T3 (da) | 2014-03-19 | 2022-03-28 | Infinity Pharmaceuticals Inc | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser |
WO2015153516A1 (en) * | 2014-04-04 | 2015-10-08 | University Of Florida Research Foundation | Hdac inhibitor compounds and methods of treatment |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
KR20180058741A (ko) | 2015-09-14 | 2018-06-01 | 인피니티 파마슈티칼스, 인코포레이티드 | 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법 |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
GB201918404D0 (en) * | 2019-12-13 | 2020-01-29 | Z Factor Ltd | Compounds and their use for the treatment of aplha1-antitrypsin deficiency |
KR20210116830A (ko) * | 2020-03-17 | 2021-09-28 | 충북대학교 산학협력단 | 신규한 4-옥소퀴나졸린-기반 n-하이드록시프로펜아미드 및 이의 용도 |
CN111517977B (zh) * | 2020-05-28 | 2023-05-23 | 爱斯特(成都)生物制药股份有限公司 | 一种合成2,4-二氟-3-三甲基乙酰胺基苯甲酸的方法 |
AU2021288568A1 (en) | 2020-06-08 | 2023-01-19 | Annji Pharmaceutical Co., Ltd. | Quinazoline derivatives useful as selective HDAC6 inhibitors |
WO2023159155A1 (en) * | 2022-02-18 | 2023-08-24 | Pivalent Therapeutics, Inc. | Inhibitors of phosphoinositide 3-kinase (pi3k) and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003528074A (ja) * | 2000-03-24 | 2003-09-24 | メチルジーン インコーポレイテッド | ヒストン脱アセチル化酵素の阻害剤 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE666424A (ja) * | 1965-05-12 | 1966-01-05 | ||
FR6001M (ja) * | 1966-12-02 | 1968-04-29 | ||
ZA705270B (en) * | 1969-08-02 | 1971-04-28 | Sumitomo Chemical Co | Novel quinazolinone derivatives and a process for production thereof |
US4054658A (en) * | 1974-02-06 | 1977-10-18 | William H. Rorer, Inc. | Therapeutic compositions containing methaqualone |
NZ192392A (en) | 1978-12-19 | 1983-02-15 | M Ishikawa | 3-(substituted (phenyl or pyridyl)) -3,4-dihydroquinazolin-4-ones |
JP3488890B2 (ja) * | 1993-11-09 | 2004-01-19 | アグロカネショウ株式会社 | 3−n−置換キナゾリノン誘導体、その製造法および該化合物を含有する除草剤 |
EP1524262A1 (en) * | 2000-03-24 | 2005-04-20 | Methylgene, Inc. | Inhibitors of histone deacetylase |
WO2004041755A2 (en) * | 2002-11-04 | 2004-05-21 | Nps Pharmaceuticals, Inc. | Quinazolinone compounds as calcilytics |
ITMI20041869A1 (it) | 2004-10-01 | 2005-01-01 | Dac Srl | Nuovi inibitori delle istone deacetilasi |
MX2008000745A (es) * | 2005-07-15 | 2008-03-14 | Schering Corp | Derivados de quinazolina utiles en el tratamiento del cancer. |
KR101314158B1 (ko) | 2005-09-21 | 2013-10-04 | 4에스체 악티엔게젤샤프트 | 히스톤 탈아세틸 효소 억제제로서의 설포닐피롤 염산염 |
GB0525068D0 (en) * | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
GB0624187D0 (en) | 2006-12-04 | 2007-01-10 | Jackson William P | HDAC inhibitors |
WO2008087514A2 (en) | 2007-01-17 | 2008-07-24 | Orchid Research Laboratories Limited | Hdac inhibitors |
US20100261710A1 (en) | 2007-08-21 | 2010-10-14 | Arqule, Inc. | HDAC Inhibitors |
WO2009045440A1 (en) | 2007-10-01 | 2009-04-09 | Lixte Biotechnology Holdings, Inc. | Hdac inhibitors |
US8431538B2 (en) | 2009-07-22 | 2013-04-30 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods of using same |
-
2013
- 2013-04-02 ES ES13775887.6T patent/ES2630062T3/es active Active
- 2013-04-02 JP JP2015505789A patent/JP6258918B2/ja active Active
- 2013-04-02 CN CN201380030630.7A patent/CN104364237B/zh active Active
- 2013-04-02 KR KR1020147031519A patent/KR101781922B1/ko active IP Right Grant
- 2013-04-02 WO PCT/US2013/035004 patent/WO2013154870A1/en active Application Filing
- 2013-04-02 IN IN2104MUN2014 patent/IN2014MN02104A/en unknown
- 2013-04-02 AU AU2013246278A patent/AU2013246278B2/en active Active
- 2013-04-02 US US13/855,525 patent/US9387209B2/en active Active
- 2013-04-02 RU RU2014144142A patent/RU2629947C2/ru active
- 2013-04-02 BR BR112014025122-3A patent/BR112014025122B1/pt active IP Right Grant
- 2013-04-02 EP EP13775887.6A patent/EP2836484B1/en active Active
- 2013-04-10 TW TW102112723A patent/TWI481597B/zh active
-
2014
- 2014-10-07 IL IL235053A patent/IL235053A/en active IP Right Grant
-
2015
- 2015-03-23 US US14/666,169 patent/US9155739B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003528074A (ja) * | 2000-03-24 | 2003-09-24 | メチルジーン インコーポレイテッド | ヒストン脱アセチル化酵素の阻害剤 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020519567A (ja) * | 2017-05-16 | 2020-07-02 | アンジー ファーマスーティカル シーオー.,エルティーディー.Annji Pharmaceutical Co., Ltd. | ヒストンデアセチラーゼ(hdacs)阻害剤 |
JP7254028B2 (ja) | 2017-05-16 | 2023-04-07 | アンジー ファーマスーティカル シーオー.,エルティーディー. | ヒストンデアセチラーゼ(hdacs)阻害剤 |
Also Published As
Publication number | Publication date |
---|---|
EP2836484B1 (en) | 2017-06-14 |
KR20150000901A (ko) | 2015-01-05 |
JP6258918B2 (ja) | 2018-01-10 |
EP2836484A4 (en) | 2015-09-02 |
ES2630062T3 (es) | 2017-08-17 |
CN104364237A (zh) | 2015-02-18 |
AU2013246278A1 (en) | 2014-11-13 |
EP2836484A1 (en) | 2015-02-18 |
US9387209B2 (en) | 2016-07-12 |
RU2629947C2 (ru) | 2017-09-05 |
BR112014025122B1 (pt) | 2022-08-16 |
IL235053A (en) | 2017-09-28 |
IN2014MN02104A (ja) | 2015-09-04 |
BR112014025122A2 (pt) | 2021-07-06 |
TW201345898A (zh) | 2013-11-16 |
US20150196563A1 (en) | 2015-07-16 |
US9155739B2 (en) | 2015-10-13 |
WO2013154870A1 (en) | 2013-10-17 |
AU2013246278B2 (en) | 2016-11-03 |
TWI481597B (zh) | 2015-04-21 |
RU2014144142A (ru) | 2016-06-10 |
KR101781922B1 (ko) | 2017-09-26 |
CN104364237B (zh) | 2016-08-24 |
US20130267542A1 (en) | 2013-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6258918B2 (ja) | ヒストンデアセチラーゼ(hdacs)阻害剤 | |
JP7254028B2 (ja) | ヒストンデアセチラーゼ(hdacs)阻害剤 | |
JP2016511237A (ja) | 選択的hdac3阻害剤 | |
JP2015512939A5 (ja) | ||
CA2592514A1 (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
WO2019120210A1 (zh) | 一类苯并呋喃及Coumestans衍生物及其制备方法和应用 | |
WO2019196945A1 (zh) | 一种合成氘代酰胺及氘代磺酰胺的新方法 | |
CA2709068A1 (en) | Benzofuran anilide histone deacetylase inhibitors | |
AU2016415412B2 (en) | Antimetastatic 2H-selenopheno[3,2-h]chromenes, synthesis thereof, and methods of using same agents | |
CN114685382B (zh) | 具有HDACs抑制活性的喹唑啉-4-胺衍生物及其制备方法与用途 | |
WO2014000694A1 (zh) | 苯并杂环衍生物 | |
BR112013000716B1 (pt) | Compostos derivados e análogos de aril e heteroarilquinolin e composição compreendendo os ditos compostos | |
JP2022550489A (ja) | スルホ置換ビアリール化合物又はその塩並びにその調製方法及び使用 | |
JP2013523867A (ja) | Ksp阻害剤としてのトリアゾール化合物 | |
KR101571915B1 (ko) | Hdac 저해제로서의 술포닐피롤의 신규 제조 방법 | |
WO2015043487A1 (zh) | 喹唑啉类化合物及其制备方法与应用 | |
KR102439852B1 (ko) | 2-아미노퀴놀린-8-올 유도체, 및 이의 용도 | |
CN111491923A (zh) | N-(2-环己基乙基)甲酰胺衍生物、其制法与医药上的用途 | |
CN109705057B (zh) | 组蛋白去乙酰化酶抑制剂及其制备方法与用途 | |
JP2021529785A (ja) | ヘッジホッグ経路に関連する状態の治療のための化合物および方法 | |
Bryant | Palladium-Catalyzed Cyclization of Drug Candidates | |
JP2008545772A (ja) | 抗腫瘍薬として有用なケイ皮酸、フェニルプロピオル酸およびフェニルプロピオン酸誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160401 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160401 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20161020 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161115 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170606 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171003 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20171106 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171205 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171207 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6258918 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R154 | Certificate of patent or utility model (reissue) |
Free format text: JAPANESE INTERMEDIATE CODE: R154 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |